Loading…
Metabolic syndrome severity score and the progression of CKD
Background Metabolic syndrome severity, expressed by the continuous metabolic syndrome risk score (MetS score), has been demonstrated to be able to predict future health conditions. However, little is known about the association between MetS score and renal function. Methods A total of 22,719 partic...
Saved in:
| Published in: | European journal of clinical investigation 2022-01, Vol.52 (1), p.e13646-n/a |
|---|---|
| Main Authors: | , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3536-66f3520f152b80da611f0e8ca56ce8967ac00ef64d0c6ee7409584f348c1488a3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3536-66f3520f152b80da611f0e8ca56ce8967ac00ef64d0c6ee7409584f348c1488a3 |
| container_end_page | n/a |
| container_issue | 1 |
| container_start_page | e13646 |
| container_title | European journal of clinical investigation |
| container_volume | 52 |
| creator | Wu, Mingyang Shu, Yanling Wang, Lulin Song, Lulu Chen, Shuohua Liu, Yunyun Bi, Jianing Li, Dankang Yang, Yingping Hu, Yonghua Wang, Youjie Wu, Shouling Tian, Yaohua |
| description | Background
Metabolic syndrome severity, expressed by the continuous metabolic syndrome risk score (MetS score), has been demonstrated to be able to predict future health conditions. However, little is known about the association between MetS score and renal function.
Methods
A total of 22,719 participants with normal renal function ed from the Kailuan Study were followed from 2006 to 2016. The new onset of chronic kidney disease (CKD) was defined as eGFR 300 mg/dl. Progressive decline in renal function was defined as an annual change rate of eGFR below the 10th percentile of the whole population.
Results
In the multivariate‐adjusted model, we found that the risk of progressive decline in renal function increased consistently with the MetS score, with an odds ratio of 1.49 (95% CI, 1.28, 1.73) for those subjects>75th percentile compared with those 75th percentile compared with those |
| doi_str_mv | 10.1111/eci.13646 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2614052635</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2614052635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3536-66f3520f152b80da611f0e8ca56ce8967ac00ef64d0c6ee7409584f348c1488a3</originalsourceid><addsrcrecordid>eNp1kDtPwzAUhS0EoqUw8AeQJSaGtH7FcSUWFMpDFLHAbLnONaRq42KnoPx7DCls3OUsn75zdRA6pWRM003A1mPKpZB7aJgyzxiXbB8NCaEiY9OCDdBRjEtCiKKcHaIBF3RaSM6H6PIRWrPwq9ri2DVV8GvAET4g1G2Ho_UBsGkq3L4B3gT_GiDG2jfYO1w-XB-jA2dWEU52OUIvN7Pn8i6bP93el1fzzPKcy0xKx3NGHM3ZQpHKSEodAWVNLi2oqSyMJQScFBWxEqAQZJor4bhQlgqlDB-h896bXnjfQmz10m9Dkyo1k1SQnMlUNEIXPWWDjzGA05tQr03oNCX6eyeddtI_OyX2bGfcLtZQ_ZG_wyRg0gOf9Qq6_016Vt73yi87S2-U</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2614052635</pqid></control><display><type>article</type><title>Metabolic syndrome severity score and the progression of CKD</title><source>Wiley</source><creator>Wu, Mingyang ; Shu, Yanling ; Wang, Lulin ; Song, Lulu ; Chen, Shuohua ; Liu, Yunyun ; Bi, Jianing ; Li, Dankang ; Yang, Yingping ; Hu, Yonghua ; Wang, Youjie ; Wu, Shouling ; Tian, Yaohua</creator><creatorcontrib>Wu, Mingyang ; Shu, Yanling ; Wang, Lulin ; Song, Lulu ; Chen, Shuohua ; Liu, Yunyun ; Bi, Jianing ; Li, Dankang ; Yang, Yingping ; Hu, Yonghua ; Wang, Youjie ; Wu, Shouling ; Tian, Yaohua</creatorcontrib><description>Background
Metabolic syndrome severity, expressed by the continuous metabolic syndrome risk score (MetS score), has been demonstrated to be able to predict future health conditions. However, little is known about the association between MetS score and renal function.
Methods
A total of 22,719 participants with normal renal function ed from the Kailuan Study were followed from 2006 to 2016. The new onset of chronic kidney disease (CKD) was defined as eGFR <60 ml/min per 1.73 m2 and/or proteinuria >300 mg/dl. Progressive decline in renal function was defined as an annual change rate of eGFR below the 10th percentile of the whole population.
Results
In the multivariate‐adjusted model, we found that the risk of progressive decline in renal function increased consistently with the MetS score, with an odds ratio of 1.49 (95% CI, 1.28, 1.73) for those subjects>75th percentile compared with those <25th percentile. Additionally, a high MetS score was found to be associated with an increased risk of CKD, with a hazard ratio of 1.53 (95% CI, 1.33, 1.78) for subjects >75th percentile compared with those <25th percentile.
Conclusions
Our findings suggested that the MetS score was associated with an increased risk of a progressive decline in renal function and was also a strong and independent risk factor for the development of CKD. These findings provide evidence of the potential clinical utility of the MetS score for assessing metabolic syndrome severity to detect the risk of decreased renal function and CKD.</description><identifier>ISSN: 0014-2972</identifier><identifier>EISSN: 1365-2362</identifier><identifier>DOI: 10.1111/eci.13646</identifier><identifier>PMID: 34197633</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; chronic kidney disease ; Cohort analysis ; cohort study ; Disease Progression ; Epidermal growth factor receptors ; Female ; Humans ; Kidney diseases ; Male ; Metabolic disorders ; Metabolic syndrome ; Metabolic Syndrome - complications ; Metabolic Syndrome - diagnosis ; metabolic syndrome severity ; Middle Aged ; progressive decline in renal function ; Proteinuria ; Renal function ; Renal Insufficiency, Chronic - epidemiology ; Renal Insufficiency, Chronic - etiology ; Risk analysis ; Risk Factors ; Severity of Illness Index</subject><ispartof>European journal of clinical investigation, 2022-01, Vol.52 (1), p.e13646-n/a</ispartof><rights>2021 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.</rights><rights>Copyright © 2022 Stichting European Society for Clinical Investigation Journal Foundation</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3536-66f3520f152b80da611f0e8ca56ce8967ac00ef64d0c6ee7409584f348c1488a3</citedby><cites>FETCH-LOGICAL-c3536-66f3520f152b80da611f0e8ca56ce8967ac00ef64d0c6ee7409584f348c1488a3</cites><orcidid>0000-0002-9853-6991</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34197633$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wu, Mingyang</creatorcontrib><creatorcontrib>Shu, Yanling</creatorcontrib><creatorcontrib>Wang, Lulin</creatorcontrib><creatorcontrib>Song, Lulu</creatorcontrib><creatorcontrib>Chen, Shuohua</creatorcontrib><creatorcontrib>Liu, Yunyun</creatorcontrib><creatorcontrib>Bi, Jianing</creatorcontrib><creatorcontrib>Li, Dankang</creatorcontrib><creatorcontrib>Yang, Yingping</creatorcontrib><creatorcontrib>Hu, Yonghua</creatorcontrib><creatorcontrib>Wang, Youjie</creatorcontrib><creatorcontrib>Wu, Shouling</creatorcontrib><creatorcontrib>Tian, Yaohua</creatorcontrib><title>Metabolic syndrome severity score and the progression of CKD</title><title>European journal of clinical investigation</title><addtitle>Eur J Clin Invest</addtitle><description>Background
Metabolic syndrome severity, expressed by the continuous metabolic syndrome risk score (MetS score), has been demonstrated to be able to predict future health conditions. However, little is known about the association between MetS score and renal function.
Methods
A total of 22,719 participants with normal renal function ed from the Kailuan Study were followed from 2006 to 2016. The new onset of chronic kidney disease (CKD) was defined as eGFR <60 ml/min per 1.73 m2 and/or proteinuria >300 mg/dl. Progressive decline in renal function was defined as an annual change rate of eGFR below the 10th percentile of the whole population.
Results
In the multivariate‐adjusted model, we found that the risk of progressive decline in renal function increased consistently with the MetS score, with an odds ratio of 1.49 (95% CI, 1.28, 1.73) for those subjects>75th percentile compared with those <25th percentile. Additionally, a high MetS score was found to be associated with an increased risk of CKD, with a hazard ratio of 1.53 (95% CI, 1.33, 1.78) for subjects >75th percentile compared with those <25th percentile.
Conclusions
Our findings suggested that the MetS score was associated with an increased risk of a progressive decline in renal function and was also a strong and independent risk factor for the development of CKD. These findings provide evidence of the potential clinical utility of the MetS score for assessing metabolic syndrome severity to detect the risk of decreased renal function and CKD.</description><subject>Adult</subject><subject>chronic kidney disease</subject><subject>Cohort analysis</subject><subject>cohort study</subject><subject>Disease Progression</subject><subject>Epidermal growth factor receptors</subject><subject>Female</subject><subject>Humans</subject><subject>Kidney diseases</subject><subject>Male</subject><subject>Metabolic disorders</subject><subject>Metabolic syndrome</subject><subject>Metabolic Syndrome - complications</subject><subject>Metabolic Syndrome - diagnosis</subject><subject>metabolic syndrome severity</subject><subject>Middle Aged</subject><subject>progressive decline in renal function</subject><subject>Proteinuria</subject><subject>Renal function</subject><subject>Renal Insufficiency, Chronic - epidemiology</subject><subject>Renal Insufficiency, Chronic - etiology</subject><subject>Risk analysis</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><issn>0014-2972</issn><issn>1365-2362</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kDtPwzAUhS0EoqUw8AeQJSaGtH7FcSUWFMpDFLHAbLnONaRq42KnoPx7DCls3OUsn75zdRA6pWRM003A1mPKpZB7aJgyzxiXbB8NCaEiY9OCDdBRjEtCiKKcHaIBF3RaSM6H6PIRWrPwq9ri2DVV8GvAET4g1G2Ho_UBsGkq3L4B3gT_GiDG2jfYO1w-XB-jA2dWEU52OUIvN7Pn8i6bP93el1fzzPKcy0xKx3NGHM3ZQpHKSEodAWVNLi2oqSyMJQScFBWxEqAQZJor4bhQlgqlDB-h896bXnjfQmz10m9Dkyo1k1SQnMlUNEIXPWWDjzGA05tQr03oNCX6eyeddtI_OyX2bGfcLtZQ_ZG_wyRg0gOf9Qq6_016Vt73yi87S2-U</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Wu, Mingyang</creator><creator>Shu, Yanling</creator><creator>Wang, Lulin</creator><creator>Song, Lulu</creator><creator>Chen, Shuohua</creator><creator>Liu, Yunyun</creator><creator>Bi, Jianing</creator><creator>Li, Dankang</creator><creator>Yang, Yingping</creator><creator>Hu, Yonghua</creator><creator>Wang, Youjie</creator><creator>Wu, Shouling</creator><creator>Tian, Yaohua</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><orcidid>https://orcid.org/0000-0002-9853-6991</orcidid></search><sort><creationdate>202201</creationdate><title>Metabolic syndrome severity score and the progression of CKD</title><author>Wu, Mingyang ; Shu, Yanling ; Wang, Lulin ; Song, Lulu ; Chen, Shuohua ; Liu, Yunyun ; Bi, Jianing ; Li, Dankang ; Yang, Yingping ; Hu, Yonghua ; Wang, Youjie ; Wu, Shouling ; Tian, Yaohua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3536-66f3520f152b80da611f0e8ca56ce8967ac00ef64d0c6ee7409584f348c1488a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>chronic kidney disease</topic><topic>Cohort analysis</topic><topic>cohort study</topic><topic>Disease Progression</topic><topic>Epidermal growth factor receptors</topic><topic>Female</topic><topic>Humans</topic><topic>Kidney diseases</topic><topic>Male</topic><topic>Metabolic disorders</topic><topic>Metabolic syndrome</topic><topic>Metabolic Syndrome - complications</topic><topic>Metabolic Syndrome - diagnosis</topic><topic>metabolic syndrome severity</topic><topic>Middle Aged</topic><topic>progressive decline in renal function</topic><topic>Proteinuria</topic><topic>Renal function</topic><topic>Renal Insufficiency, Chronic - epidemiology</topic><topic>Renal Insufficiency, Chronic - etiology</topic><topic>Risk analysis</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wu, Mingyang</creatorcontrib><creatorcontrib>Shu, Yanling</creatorcontrib><creatorcontrib>Wang, Lulin</creatorcontrib><creatorcontrib>Song, Lulu</creatorcontrib><creatorcontrib>Chen, Shuohua</creatorcontrib><creatorcontrib>Liu, Yunyun</creatorcontrib><creatorcontrib>Bi, Jianing</creatorcontrib><creatorcontrib>Li, Dankang</creatorcontrib><creatorcontrib>Yang, Yingping</creatorcontrib><creatorcontrib>Hu, Yonghua</creatorcontrib><creatorcontrib>Wang, Youjie</creatorcontrib><creatorcontrib>Wu, Shouling</creatorcontrib><creatorcontrib>Tian, Yaohua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>European journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wu, Mingyang</au><au>Shu, Yanling</au><au>Wang, Lulin</au><au>Song, Lulu</au><au>Chen, Shuohua</au><au>Liu, Yunyun</au><au>Bi, Jianing</au><au>Li, Dankang</au><au>Yang, Yingping</au><au>Hu, Yonghua</au><au>Wang, Youjie</au><au>Wu, Shouling</au><au>Tian, Yaohua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metabolic syndrome severity score and the progression of CKD</atitle><jtitle>European journal of clinical investigation</jtitle><addtitle>Eur J Clin Invest</addtitle><date>2022-01</date><risdate>2022</risdate><volume>52</volume><issue>1</issue><spage>e13646</spage><epage>n/a</epage><pages>e13646-n/a</pages><issn>0014-2972</issn><eissn>1365-2362</eissn><abstract>Background
Metabolic syndrome severity, expressed by the continuous metabolic syndrome risk score (MetS score), has been demonstrated to be able to predict future health conditions. However, little is known about the association between MetS score and renal function.
Methods
A total of 22,719 participants with normal renal function ed from the Kailuan Study were followed from 2006 to 2016. The new onset of chronic kidney disease (CKD) was defined as eGFR <60 ml/min per 1.73 m2 and/or proteinuria >300 mg/dl. Progressive decline in renal function was defined as an annual change rate of eGFR below the 10th percentile of the whole population.
Results
In the multivariate‐adjusted model, we found that the risk of progressive decline in renal function increased consistently with the MetS score, with an odds ratio of 1.49 (95% CI, 1.28, 1.73) for those subjects>75th percentile compared with those <25th percentile. Additionally, a high MetS score was found to be associated with an increased risk of CKD, with a hazard ratio of 1.53 (95% CI, 1.33, 1.78) for subjects >75th percentile compared with those <25th percentile.
Conclusions
Our findings suggested that the MetS score was associated with an increased risk of a progressive decline in renal function and was also a strong and independent risk factor for the development of CKD. These findings provide evidence of the potential clinical utility of the MetS score for assessing metabolic syndrome severity to detect the risk of decreased renal function and CKD.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>34197633</pmid><doi>10.1111/eci.13646</doi><tpages>0</tpages><orcidid>https://orcid.org/0000-0002-9853-6991</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-2972 |
| ispartof | European journal of clinical investigation, 2022-01, Vol.52 (1), p.e13646-n/a |
| issn | 0014-2972 1365-2362 |
| language | eng |
| recordid | cdi_proquest_journals_2614052635 |
| source | Wiley |
| subjects | Adult chronic kidney disease Cohort analysis cohort study Disease Progression Epidermal growth factor receptors Female Humans Kidney diseases Male Metabolic disorders Metabolic syndrome Metabolic Syndrome - complications Metabolic Syndrome - diagnosis metabolic syndrome severity Middle Aged progressive decline in renal function Proteinuria Renal function Renal Insufficiency, Chronic - epidemiology Renal Insufficiency, Chronic - etiology Risk analysis Risk Factors Severity of Illness Index |
| title | Metabolic syndrome severity score and the progression of CKD |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A46%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metabolic%20syndrome%20severity%20score%20and%20the%20progression%20of%20CKD&rft.jtitle=European%20journal%20of%20clinical%20investigation&rft.au=Wu,%20Mingyang&rft.date=2022-01&rft.volume=52&rft.issue=1&rft.spage=e13646&rft.epage=n/a&rft.pages=e13646-n/a&rft.issn=0014-2972&rft.eissn=1365-2362&rft_id=info:doi/10.1111/eci.13646&rft_dat=%3Cproquest_cross%3E2614052635%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3536-66f3520f152b80da611f0e8ca56ce8967ac00ef64d0c6ee7409584f348c1488a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2614052635&rft_id=info:pmid/34197633&rfr_iscdi=true |